Rochester’s Cognivue Inc. has been selected by the Global Alzheimer’s Platform (GAP) to participate in its pioneering Bio-Hermes clinical trial study. Also participating in the study are Eli Lilly & Co., AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation and other respected biopharma, technology and nonprofit entities.
Bio Hermes is the first platform study to investigate and compare blood-based biomarkers, digital markers and legacy assessments in 1,000 people over the age of 60 screened for preclinical Alzheimer’s Disease (AD), prodromal AD, or mild dementia AD. The use of biomarkers could lead to earlier and more frequent detection of amyloid build-up, prompting those affected to seek early intervention, including participation in clinical trials for Alzheimer’s prevention or treatment.
“We are excited about the collaboration with the Global Alzheimer’s Project and the opportunity to be part of the groundbreaking Bio-Hermes clinical study. This is the first wide-scale application of Cognivue technology along with state-of-the-art frontline diagnostic tools such as blood-based biomarkers and brain image scanning. This could be a milestone development to create a gold standard for the future of Alzheimer’s Disease assessment and diagnostics,” said Cognivue President and CEO Tom O’Neill. “Our ability to objectively, quantitatively, and reliably identify cognitive status further assist with the accurate diagnosis for potential cognitive impairment, which can then be treated or managed.”
Cognviue’s technologies are designed to give health care providers a useful tool for cognitive evaluation and diagnosis. The digital system is engineered to eliminate bias and variability throughout the test that establishes cognitive baselines and provides a concurrent monitoring vehicle for the evaluation and treatment of cognitive issues over time.
“The Bio-Hermes clinical trial will evaluate the most promising digital and blood biomarker tests, and we’re pleased to have Cognivue as one of our digital assessments for cognitive function,” said John Dwyer, president of the Global Alzheimer’s Platform Foundation. “This self-administered test could allow medical practices in any community to detect cognitive decline and prompt steps to diagnose Alzheimer’s. In turn, that means patients will be able to make timely decisions about treatment or participation in research.”
Cognivue is a neuroscience company focused on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on cortical information processing by testing key cognitive domains.
[email protected] / 585-653-4021
Follow Velvet Spicer on Twitter: @Velvet_Spicer